- Home
- ZUMZ vs ENGN Comparison
ZUMZ vs ENGN Comparison
Compare ZUMZ & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZUMZ
- ENGN
- Stock Information
- Founded
- ZUMZ 1978
- ENGN 1999
- Country
- ZUMZ United States
- ENGN Canada
- Employees
- ZUMZ N/A
- ENGN N/A
- Industry
- ZUMZ Clothing/Shoe/Accessory Stores
- ENGN
- Sector
- ZUMZ Consumer Discretionary
- ENGN
- Exchange
- ZUMZ Nasdaq
- ENGN Nasdaq
- Market Cap
- ZUMZ 211.6M
- ENGN 191.1M
- IPO Year
- ZUMZ 2005
- ENGN N/A
- Fundamental
- Price
- ZUMZ $14.01
- ENGN $3.94
- Analyst Decision
- ZUMZ Hold
- ENGN Buy
- Analyst Count
- ZUMZ 1
- ENGN 7
- Target Price
- ZUMZ $25.00
- ENGN $23.29
- AVG Volume (30 Days)
- ZUMZ 174.1K
- ENGN 106.0K
- Earning Date
- ZUMZ 09-04-2025
- ENGN 09-09-2025
- Dividend Yield
- ZUMZ N/A
- ENGN N/A
- EPS Growth
- ZUMZ N/A
- ENGN N/A
- EPS
- ZUMZ 0.04
- ENGN N/A
- Revenue
- ZUMZ $896,157,000.00
- ENGN N/A
- Revenue This Year
- ZUMZ $3.31
- ENGN N/A
- Revenue Next Year
- ZUMZ $1.34
- ENGN N/A
- P/E Ratio
- ZUMZ $358.62
- ENGN N/A
- Revenue Growth
- ZUMZ 3.01
- ENGN N/A
- 52 Week Low
- ZUMZ $11.31
- ENGN $2.65
- 52 Week High
- ZUMZ $31.37
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- ZUMZ 51.81
- ENGN 59.94
- Support Level
- ZUMZ $13.08
- ENGN $3.45
- Resistance Level
- ZUMZ $15.36
- ENGN $4.15
- Average True Range (ATR)
- ZUMZ 0.57
- ENGN 0.28
- MACD
- ZUMZ -0.10
- ENGN 0.02
- Stochastic Oscillator
- ZUMZ 40.79
- ENGN 70.00
About ZUMZ Zumiez Inc.
Zumiez Inc is a United-States-based specialty retailer engaged in the sale of apparel, footwear, accessories, and hard goods. The company provides merchandise with cultural elements coming from fashion, music, art from action sports, streetwear, and other lifestyles. The company operates under the brands Zumiez, Fast Times, and Blue Tomato, and through both physical stores and websites. The majority of the company's stores are located in the U.S., with the rest in Canada, Australia, and Europe. The U.S. market contributes to the majority of the company's revenue.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.